How Does Lerodalcibep Compare to Other PCSK9 Inhibitors?

July 2026

Rx lerodalcibep (Lerochol) is a new subcutaneous self-injectable med for high cholesterol.

You’ll hear it’s a third generation PCSK9 inhibitor. It works as a small protein that binds to PCSK9 in the blood and blocks its effects.

Alirocumab (Praluent) and evolocumab (Repatha) are monoclonal antibodies that bind to PCSK9...and inclisiran (Leqvio) is a small interfering RNA that prevents formation of the PCSK9 protein in the liver.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote